Effects of early medication treatment and metformin use for cancer prevention in diabetes patients: a nationwide sample cohort study using extended landmark-time analysis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
OBJECTIVES: This study investigated the effectiveness of early medication treatment and metformin use for cancer prevention in type 2 diabetes patients. METHODS: Population-based cohort data were used from the Korean National Health Insurance Service-National Sample Cohort database (KNHIS-NSC) for 2002–2013. Patient-specific medication prescription status was defined by the landmark time (LMT; a fixed time after cohort entry), considering both pre- and post-LMT prescriptions to control methodological biases in observational research. The LMT was set to 2 years. Logistic regression analysis with multivariable adjustment was conducted to analyze cancer incidence by patient-specific medication prescription status. RESULTS: Only 33.4% of the subjects were prescribed medication early (before the LMT) with compliance. Cancer incidence in individuals with early prescription and compliance was 25% lower (odds ratio [OR],0.75; 95% confidence interval [CI], 0.67 to 0.84) than in those without. As early-prescribed medications, metformin monotherapy and metformin combination therapy were associated with 34% (OR, 0.66; 95% CI, 0.51 to 0.83) and 25% (OR, 0.75; 95% CI, 0.64 to 0.88) lower cancer risk than nonuse, respectively. Patients who were prescribed late (post-LMT) but did not comply with the prescription had a 24% (OR, 1.24; 95% CI, 0.97 to 1.58) higher cancer incidence than non-users. Among patients who started monotherapy early without changes throughout the entire follow-up period, those who started on metformin had a 37% (OR, 0.63; 95% CI, 0.41 to 0.99) lower risk of cancer than non-metformin users. CONCLUSIONS: Doctors must prescribe antidiabetic medication early, and patient compliance is required, regardless of the prescription time, to prevent cancer. Metformin monotherapy or combination therapy is recommended as an early prescription.
Abstract
OBJECTIVES: This study investigated the effectiveness of early medication treatment and metformin use for cancer prevention in type 2 diabetes patients. METHODS: Population-based cohort data were used from the Korean National Health Insurance Service-National Sample Cohort database (KNHIS-NSC) for 2002–2013. Patient-specific medication prescription status was defined by the landmark time (LMT; a fixed time after cohort entry), considering both pre- and post-LMT prescriptions to control methodological biases in observational research. The LMT was set to 2 years. Logistic regression analysis with multivariable adjustment was conducted to analyze cancer incidence by patient-specific medication prescription status. RESULTS: Only 33.4% of the subjects were prescribed medication early (before the LMT) with compliance. Cancer incidence in individuals with early prescription and compliance was 25% lower (odds ratio [OR],0.75; 95% confidence interval [CI], 0.67 to 0.84) than in those without. As early-prescribed medications, metformin monotherapy and metformin combination therapy were associated with 34% (OR, 0.66; 95% CI, 0.51 to 0.83) and 25% (OR, 0.75; 95% CI, 0.64 to 0.88) lower cancer risk than nonuse, respectively. Patients who were prescribed late (post-LMT) but did not comply with the prescription had a 24% (OR, 1.24; 95% CI, 0.97 to 1.58) higher cancer incidence than non-users. Among patients who started monotherapy early without changes throughout the entire follow-up period, those who started on metformin had a 37% (OR, 0.63; 95% CI, 0.41 to 0.99) lower risk of cancer than non-metformin users. CONCLUSIONS: Doctors must prescribe antidiabetic medication early, and patient compliance is required, regardless of the prescription time, to prevent cancer. Metformin monotherapy or combination therapy is recommended as an early prescription.
참고문헌 (50)
- Saeedi P, "Global and regional diabetes prevalence estimates for 2019and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition", Diabetes Res Clin Pract, 157, pp.107843~ (2019)
- Yoonjung Kim, "Trends in the prevalence and management of major metabolic risk factors for chronic disease over 20 years: Findings from the 1998–2018 Korea National Health and Nutrition Examination Survey", Epidemiology and Health, 43, pp.1~12 (2021), 한국역학회[DOI]
- Saraei P, "The beneficial effects of metformin on cancer prevention and therapy : a comprehensive review of recent advances", Cancer Manag Res, 11, pp.3295~3313 (2019)
- Kim HJ, "Insulin resistance and cancer", Korean J Epidemiol, 27, pp.38~50 (2005)
- Suk Kyeong Kim, "Site-specific cancer risk in patients with type 2 diabetes: a nationwide population-based cohort study in Korea", The Korean Journal of Internal Medicine, 35(3), pp.641~651 (2020), 대한내과학회[DOI]
- Ma X, "Global burden of cancer", Yale J Biol Med, 79, pp.85~94 (2006)
- Laiteerapong N, "The legacy effect in type 2 diabetes : impact of early glycemic control on future complications(the diabetes & aging study)", Diabetes Care, 42, pp.416~426 (2019)
- Kim YY, "Effect of medication adherence on long-term all-cause-mortality and hospitalization for cardiovascular disease in 65, 067 newly diagnosed type 2 diabetes patients", Sci Rep, 8, pp.12190~ (2018)
- Pratley RE, "The early treatment of type 2 diabetes", Am J Med, 126(9 Suppl 1), pp.S2~S9 (2013)
- Chong S, "Lifestyle changes after a diagnosis of type 2 diabetes", Diabetes Spectr, 30, pp.43~50 (2017)
- McKenzie MC, "Medication adherence improvements in employees participating in a pharmacist-run risk reduction program", Inov Pharm, 3, pp.92~ (2012)
- Osterberg L, "Adherence to medication", N Engl J Med, 353, pp.487~497 (2005)
- 박일수, "Effect of Medicine Adherence on the Occurrence of Cerebrovascular Disorders in Diabetes Mellitus Patients", Epidemiology and Health, 33, pp.1~6 (2011), 한국역학회
- UK Prospective Diabetes Study(UKPDS)Group, "Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes(UKPDS 34)", Lancet, 352, pp.854~865 (1998)
- Palmer SC, "Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes : a meta-analysis", JAMA, 316, pp.313~324 (2016)
- Kwon S, "The longterm effects of metformin on patients with type 2 diabetic kidney disease", Diabetes Care, 43, pp.948~955 (2020)
- Evans JM, "Metformin and reduced risk of cancer in diabetic patients", BMJ, 330, pp.1304~1305 (2005)
- Libby G, "New users of metformin are at low risk of incident cancer : a cohort study among people with type 2 diabetes", Diabetes Care, 32, pp.1620~1625 (2009)
- Lee MS, "Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese : a rep-resentative population prospective cohort study of 800, 000 individuals", BMC Cancer, 11, pp.20~ (2011)
- Monami M, "Metformin and cancer occurrence in insulin-treated type 2 diabetic patients", Diabetes Care, 34, pp.129~131 (2011)
- Chlebowski RT, "Diabetes, metformin, and breast cancer in postmenopausal women", J Clin Oncol, 30, pp.2844~2852 (2012)
- Ma SJ, "Metformin use improves survival of diabetic liver cancer patients : systematic review and meta-analysis", Oncotarget, 7, pp.66202~66211 (2016)
- Wang YW, "Metformin : a review of its potential indications", Drug Des Devel Ther, 11, pp.2421~2429 (2017)
- Kim YS, "Metformin use reduced the overall risk of cancer in diabetic patients : a study based on the Korean NHIS-HEALS cohort", Nutr Metab Cardiovasc Dis, 30, pp.1714~1722 (2020)
- Suissa S, "Metformin to treat cancer : misstep in translational research from observational studies", Epidemiology, 28, pp.455~458 (2017)
- Kheirandish M, "Anti-cancer effects of metformin : recent evidences for its role in prevention and treatment of cancer", Curr Drug Metab, 19, pp.793~797 (2018)
- Oh TK, "Metformin use and the risk of cancer in patients with diabetes: a nationwide sample cohort study", Cancer Prev Res(Phila), 13, pp.195~202 (2020)
- Dankner R, "Metformin treatment and cancer risk : cox regression analysis, with time-dependent covariates, of 320, 000 persons with incident diabetes mellitus", Am J Epidemiol, 188, pp.1794~1800 (2019)
- Hong JL, "Comparative effect of initiating metformin versus sulfonylureas on breast cancer risk in older women", Epidemiology, 28, pp.446~454 (2017)
- Smiechowski BB, "The use of metformin and the incidence of lung cancer in patients with type 2 diabetes", Diabetes Care, 36, pp.124~129 (2013)
- Suissa S, "Metformin and the risk of cancer : time-related biases in observational studies", Diabetes Care, 35, pp.2665~2673 (2012)
- Suissa S, "Immortal time bias in pharmaco-epidemiology", Am J Epidemiol, 167, pp.492~499 (2008)
- Suissa S, "Time-window bias in case-control studies : statins and lung cancer", Epidemiology, 22, pp.228~231 (2011)
- Lévesque LE, "Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes", BMJ, 340, pp.b5087~ (2010)
- Anderson JR, "Analysis of survival by tumor response", J Clin Oncol, 1, pp.710~719 (1983)
- Mi X, "Impact of immortal person-time and time scale in comparative effectiveness research for medical devices : a case for implantable cardioverterdefibrillators", J Clin Epidemiol, 66(8 Suppl), pp.S138~S144 (2013)
- Mi X, "Use of the landmark method to address immortal person-time bias in comparative effectiveness research : a simulation study", Stat Med, 35, pp.4824~4836 (2016)
- Lee J, "Cohort profile : the National Health Insurance Service-National Sample Cohort(NHISNSC), South Korea", Int J Epidemiol, 46, pp.e15~ (2017)
- Hwangbo Y, "Incidence of diabetes after cancer development : a Korean national cohort study", JAMA Oncol, 4, pp.1099~1105 (2018)
- Ballotari P, "Diabetes and risk of cancer incidence : results from a population-based cohort study in northern Italy", BMC Cancer, 17, pp.703~ (2017)
- Wang CP, "Frailty attenuates the impact of metformin on reducing mortality in older adults with type 2diabetes", J Endocrinol Diabetes Obes, 2, pp.1031~ (2014)
- Currie CJ, "The influence of glucose-lowering therapies on cancer risk in type 2 diabetes", Diabetologia, 52, pp.1766~1777 (2009)
- Dafni U, "Landmark analysis at the 25-year landmark point", Circ Cardiovasc Qual Outcomes, 4, pp.363~371 (2011)
- George A, "What’s the risk: differentiating risk ratios, odds ratios, and hazard ratios?", Cureus, 12, pp.e10047~ (2020)
- Knol MJ, "How to deal with measures of association : a short guide for the clinician", Cerebrovasc Dis, 33, pp.98~103 (2012)
- You JH, "Metformin and gastrointestinal cancer development in newly diagnosed type 2 diabetes : a population-based study in Korea", Clin Transl Gastroenterol, 11, pp.e00254~ (2020)
- Kim J, "Diabetes, metformin, and lung cancer : retrospective study of the Korean NHIS-HEALS database", Clin Lung Cancer, 21, pp.e551~e559 (2020)
- Shin CM, "Anti-diabetic medications and the risk for colorectal cancer : a population-based nested case-control study", Cancer Epidemiol, 64, pp.101658~ (2020)
- Yoshida K, "Active-comparator design and new-user design in observational studies", Nat Rev Rheumatol, 11, pp.437~441 (2015)
- Noh Y, "Durability of initial antidiabetic monotherapy and subsequent treatment adjustment patterns among newly treated type 2 diabetes patients", Ther Clin Risk Manag, 14, pp.1563~1571 (2018)